Citigroup
JBIO

Citigroup’s Jade Biosciences JBIO Stock Holding History

Citigroup’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Buy
54,380
+46,764
+614% +$975K ﹤0.01% 3311
2026
Q1 		$107K Buy
7,616
+6,281
+470% +$90.9K ﹤0.01% 4259
2025
Q4 		$20.6K Sell
1,335
-257
-16% -$3.02K ﹤0.01% 4863
2025
Q3 		$13.7K Sell
1,592
-10,551
-87% -$86.2K ﹤0.01% 4931
2025
Q2 		$121K Buy
12,143
+11,652
+2,373% +$397K ﹤0.01% 4319
2025
Q1 		$43.1K Buy
491
+28
+6% +$2.46K ﹤0.01% 4915
2024
Q4 		$43K Sell
463
-6,206
-93% -$535K ﹤0.01% 5125
2024
Q3 		$488K Buy
6,669
+6,568
+6,503% +$424K ﹤0.01% 3743
2024
Q2 		$5.88K Buy
101
+28
+38% +$18.6K ﹤0.01% 5235
2024
Q1 		$75.3K Buy
73
+13
+22% +$9.93K ﹤0.01% 4420
2023
Q4 		$47.4K Buy
60
+54
+900% +$27.5K ﹤0.01% 4550
2023
Q3 		$2.89K Sell
6
-89
-94% -$48.2K ﹤0.01% 4865
2023
Q2 		$57K Buy
95
+88
+1,257% +$56.3K ﹤0.01% 4565
2023
Q1 		$4.62K Sell
7
-3
-30% -$2.49K ﹤0.01% 4961
2022
Q4 		$10.2K Sell
10
-5
-33% -$3.63K ﹤0.01% 4831
2022
Q3 		$8K Sell
15
-16
-52% -$10.7K ﹤0.01% 5054
2022
Q2 		$17K Sell
31
-10
-24% -$4.78K ﹤0.01% 5089
2022
Q1 		$26K Sell
41
-58
-59% -$22.5K ﹤0.01% 5016
2021
Q4 		$41K Buy
99
+66
+200% +$33.4K ﹤0.01% 5156
2021
Q3 		$24K Buy
+33
New +$18.5K ﹤0.01% 5148

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's JBIO Position: Q2 2026 in Review

Citigroup increased its Jade Biosciences (JBIO) stake by 614% in Q2 2026, buying an estimated $975K and bringing the position to 54,380 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3311.

Citigroup first reported a position in JBIO in Q3 2021 and has held it in 20 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Citigroup held 54,380 shares of Jade Biosciences worth $1.21M as of Q2 2026.
  • Citigroup bought 46,764 Jade Biosciences shares in Q2 2026, an estimated $975K.
  • Jade Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3311 holding.
  • Citigroup first reported a position in Jade Biosciences in Q3 2021 and has held it in 20 quarters since.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.